Literature DB >> 15340031

Severe hypothyroidism after thalidomide treatment.

Nicola de Savary1, Richard Lee, Bijay Vaidya.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15340031      PMCID: PMC1079593          DOI: 10.1177/014107680409700914

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  3 in total

1.  Hypothyroidism in patients with multiple myeloma following treatment with thalidomide.

Authors:  Ashraf Z Badros; Eric Siegel; Donald Bodenner; Maurizio Zangari; Jerome Zeldis; Bart Barlogie; Guido Tricot
Journal:  Am J Med       Date:  2002-04-01       Impact factor: 4.965

Review 2.  Thalidomide: current and potential clinical applications.

Authors:  L Calabrese; A B Fleischer
Journal:  Am J Med       Date:  2000-04-15       Impact factor: 4.965

3.  Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug.

Authors:  G F SOMERS
Journal:  Br J Pharmacol Chemother       Date:  1960-03
  3 in total
  4 in total

Review 1.  Thyroid dysfunction from antineoplastic agents.

Authors:  Ole-Petter Riksfjord Hamnvik; P Reed Larsen; Ellen Marqusee
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506

2.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Authors:  Waqas Rehman; Lisa M Arfons; Hillard M Lazarus
Journal:  Ther Adv Hematol       Date:  2011-10

Review 3.  Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

Authors:  Francesco Torino; Salvatore Maria Corsello; Raffaele Longo; Agnese Barnabei; Giampietro Gasparini
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

4.  Thyroid dysfunction in Khyber Pakhtunkhwa, Pakistan.

Authors:  Shahnaz Attaullah; Bibi Safia Haq; Mairman Muska
Journal:  Pak J Med Sci       Date:  2016 Jan-Feb       Impact factor: 1.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.